Market LIVE
Published markets; coverage varies by country
Product profile · United States

Rybrevant Faspro

 ·  Patent Litigation & Settlement History ↓

Ingredientamivantamab and hyaluronidase-lpuj
Application typeBLA
Application761484
Product004
Dosage formInjection
RouteSubcutaneous
Strength3,520MG/22ML; 44,000UNITS (160MG/2,000UNITS/ML)
Approval date2026-02-13
Marketing statusPrescription
Status event—
ApplicantJANSSEN BIOTECH
Product source

Current GenericRadar decision

Year2033
SelectionCANDIDATE
ReviewFINAL_CHECKING
Anchor typeDRUG_SUBSTANCE
Anchor date2033-11-21
Patent anchor2033-11-21
Exclusivity anchor2033-05-21
Protection date—
First Final ANDA—
Status event—

GNR judgment: CANDIDATE. Reference year: 2033. Anchor type: DRUG_SUBSTANCE. Patent anchor: 2033-11-21. Exclusivity anchor: 2033-05-21. Anchor date: 2033-11-21. Patent tail: no. Exclusivity tail: no. Review status: FINAL_CHECKING. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US95931642033-11-21— —YNTRUE_DS_SCOPE_SUPPORTED
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
RPE_BASELINE2021-05-212033-05-21Full-product 12-year operational assumption; not FDA determinationYY——Source

2026-10-10 · PENDING_EXCLUSIVITY_CONFIRMATION · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (2)
TypeDateRoleBasisSource
PATENT2033-11-21ANCHOR_REFERENCEClassification includes excluded and conditional scope; use payload; current official term pendingSource
REGULATORY_EXCLUSIVITY2033-05-21SCOPE_HISTORYUser-adopted operational baseline; inherited dates do not restart RPE; not FDA determinationSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.